IQMDU has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IQMDU has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Intelligent Medicine Acquisition's Enterprise Value is $258.60 Mil. Intelligent Medicine Acquisition's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.68 Mil. Therefore, Intelligent Medicine Acquisition's EV-to-FCF for today is -379.73.
The historical rank and industry rank for Intelligent Medicine Acquisition's EV-to-FCF or its related term are showing as below:
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-06-04), Intelligent Medicine Acquisition's stock price is $10.98. Intelligent Medicine Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $0.000. Therefore, Intelligent Medicine Acquisition's PE Ratio for today is N/A.
The historical data trend for Intelligent Medicine Acquisition's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intelligent Medicine Acquisition Annual Data | |||||
Trend | Dec21 | Dec22 | |||
EV-to-FCF | - | -306.74 |
Intelligent Medicine Acquisition Quarterly Data | ||||||||
Feb21 | Jun21 | Sep21 | Dec21 | Jun22 | Sep22 | Dec22 | ||
EV-to-FCF | Get a 7-Day Free Trial | - | - | -1,932.93 | -1,137.12 | -306.74 |
For the Shell Companies subindustry, Intelligent Medicine Acquisition's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Diversified Financial Services industry and Financial Services sector, Intelligent Medicine Acquisition's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Intelligent Medicine Acquisition's EV-to-FCF falls into.
Intelligent Medicine Acquisition's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 258.595 | / | -0.681 | |
= | -379.73 |
Intelligent Medicine Acquisition's current Enterprise Value is $258.60 Mil.
Intelligent Medicine Acquisition's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intelligent Medicine Acquisition (NAS:IQMDU) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Intelligent Medicine Acquisition's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 10.98 | / | 0.000 | |
= | N/A |
Intelligent Medicine Acquisition's share price for today is $10.98.
Intelligent Medicine Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Intelligent Medicine Acquisition's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Goldman Sachs & Co. Llc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Goldman Sachs Group Inc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Saba Capital Management, L.p. | 10 percent owner | 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174 |
Boaz Weinstein | 10 percent owner | 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174 |
Joseph L Schocken | director | 2800 UNION SQUARE, 600 UNIVERSITY STREET, SEATTLE WA 98101 |
Kavita Patel | director | C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
Jack Hidary | director | 3 PARK AVENUE, NEW YORK NY 10016 |
Gregory C Simon | director, officer: CEO and CFO | 9001 BURDETTE RD., BETHESDA MD 20817 |
Patience Marime-ball | director | 9001 BURDETTE RD., BETHESDA MD 20817 |
Intelligent Medicine Sponsor Llc | 10 percent owner | 9001 BURDETTE ROAD, BETHESDA MD 20817 |
From GuruFocus
By Business Wire Business Wire • 02-03-2023
By Business Wire Business Wire • 04-26-2023
By Business Wire Business Wire • 11-10-2021
By Business Wire Business Wire • 12-23-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.